Form 4: Catalyst Pharmaceuticals Director Acquires Shares Through Vesting of Restricted Stock Units

Director David S. Tierney acquired 1,333 shares of Catalyst Pharmaceuticals common stock on December 27, 2024, through the vesting of restricted stock units.

Summary

• On December 27, 2024, David S. Tierney, a director of Catalyst Pharmaceuticals, acquired 1,333 shares of common stock due to the vesting of restricted stock units.
• These restricted stock units vest in three equal tranches annually on December 27, 2023, December 27, 2024, and December 27, 2025.
• The reported transaction increased Tierney's direct ownership to 351,620 shares of common stock.
• Tierney also holds 212,274 restricted stock units after the transaction.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard disclosure of stock vesting, neither particularly positive nor negative.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company's stock.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine vesting of previously granted equity.

Next Steps

• The reporting person will receive shares of common stock within sixty days of vesting.

Key Dates